Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Stock Position Lowered by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lowered its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 5.6% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 151,428 shares of the biopharmaceutical company’s stock after selling 9,043 shares during the quarter. Allspring Global Investments Holdings LLC owned 0.26% of Vanda Pharmaceuticals worth $856,000 at the end of the most recent quarter.

A number of other hedge funds have also recently bought and sold shares of the company. GSA Capital Partners LLP boosted its position in shares of Vanda Pharmaceuticals by 39.8% during the 4th quarter. GSA Capital Partners LLP now owns 567,756 shares of the biopharmaceutical company’s stock valued at $2,396,000 after purchasing an additional 161,737 shares in the last quarter. Sei Investments Co. grew its position in Vanda Pharmaceuticals by 39.6% in the first quarter. Sei Investments Co. now owns 518,851 shares of the biopharmaceutical company’s stock worth $2,132,000 after buying an additional 147,066 shares during the last quarter. Susquehanna Fundamental Investments LLC bought a new position in shares of Vanda Pharmaceuticals in the first quarter valued at $1,158,000. Acadian Asset Management LLC lifted its position in shares of Vanda Pharmaceuticals by 4.7% during the 1st quarter. Acadian Asset Management LLC now owns 2,370,335 shares of the biopharmaceutical company’s stock valued at $9,740,000 after acquiring an additional 107,203 shares during the last quarter. Finally, Empowered Funds LLC boosted its stake in shares of Vanda Pharmaceuticals by 8.2% during the 1st quarter. Empowered Funds LLC now owns 201,283 shares of the biopharmaceutical company’s stock worth $827,000 after acquiring an additional 15,215 shares in the last quarter. 88.14% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have recently commented on VNDA. Cantor Fitzgerald upped their target price on Vanda Pharmaceuticals from $11.00 to $13.00 and gave the company an “overweight” rating in a report on Thursday, August 1st. StockNews.com initiated coverage on shares of Vanda Pharmaceuticals in a report on Thursday, August 29th. They issued a “hold” rating for the company.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $5.08 on Thursday. The company has a market cap of $296.11 million, a P/E ratio of -63.25 and a beta of 0.77. Vanda Pharmaceuticals Inc. has a 12-month low of $3.30 and a 12-month high of $6.75. The company’s fifty day moving average is $5.56 and its two-hundred day moving average is $5.07.

Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings data on Wednesday, July 31st. The biopharmaceutical company reported ($0.08) EPS for the quarter. The business had revenue of $50.47 million for the quarter. Vanda Pharmaceuticals had a negative return on equity of 2.01% and a negative net margin of 6.00%. Equities research analysts anticipate that Vanda Pharmaceuticals Inc. will post -0.49 earnings per share for the current year.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.